Sam: Welcome to BJD Talks, the official podcast of the BJD. I'm Sam.
Meera: And I'm Meera. In this episode we will be discussing the article by Lucy Booth et al, 'Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: a scoping review,' from February, 2026 and included in the June 2026 issue.
Sam: This is a fascinating topic, Meera. Melanoma, often regarded as the deadliest form of skin cancer, is notoriously complex in terms of immunity. While immune checkpoint inhibitors, or ICIs, have revolutionised treatment, only about fifty per cent of patients see substantial benefits. This paper delves into an area that’s often overlooked—B cells and their antibodies—where traditionally, T cells have received the bulk of attention.
Meera: To evaluate what is known in the literature on B-cells and antibodies in melanoma, and their prognostic and predictive value the authors conducted a scoping review searching for original research studies published between 2000 and 2024. The search identified 80 studies that were ultimately analysed. One notable finding from the scoping review is that certain B-cell markers, especially memory B cells in melanoma tumours, are strongly associated with improved survival and better responses to ICI therapy. These memory B cells, linked to tertiary lymphoid structures, or TLS, seem crucial for fostering anti-tumour immunity.
Sam: That TLS link is especially intriguing. These are immune hubs, forming within tumours, that gather B cells, T cells, and others. The studies in the scoping review found that the presence of TLS enhances immune activity and improves immunotherapy outcomes, with B cells in particular interacting with T cells to amplify the immune response in the tumour microenvironment.
Meera: What’s striking, though, is that not all B cells are equally helpful. While memory B cells and those linked to TLS seem advantageous, subsets like regulatory B cells are associated with immunosuppressive environments and worse outcomes. For instance, regulatory B cells secrete cytokines, such as TGF-beta and IL-10, to suppress the immune attack on melanoma.
Sam: Precisely. Another area the scoping review examines is antibody isotype switching. It highlights how IgG4, a less-inflammatory antibody type, often becomes dominant in melanoma patients. Its prevalence has been linked to poorer outcomes, likely due to its ability to block pathways essential for activating robust anti-tumour immune responses, effectively shielding the tumour.
Meera: That ties neatly into humoral immunity, doesn’t it? A promising insight is that factors like B-cell receptor diversity and immunoglobulin gene rearrangements might be used as biomarkers to predict ICI responses. In essence, humoral profiles could indicate which patients are more likely to benefit, or face barriers, such as resistance or immune-related adverse events—commonly called irAEs.
Sam: The findings around irAEs are particularly intriguing, though they need further investigation. While the scoping review notes a link between autoantibody production on ICI therapy and certain toxicities, like inflammatory arthritis, it also suggests that high baseline autoantibodies might reduce the risk of developing irAEs. It’s an interesting duality.
Meera: It is, but the study’s limitations are worth acknowledging. Most of the eighty included studies were retrospective, meaning causation couldn't be firmly established. Additionally, small sample sizes and variations across studies make broader conclusions challenging. We’ll need well-designed prospective studies to validate these exciting findings.
Sam: Absolutely, though the potential is remarkable. This research not only shines a light on humoral immunity but also suggests that B cells may hold the key to advancing precision medicine in melanoma. Whether that’s through identifying biomarker signatures or understanding the roles of antibodies like IgG4, there’s much to explore. What’s your main takeaway, Meera?
Meera: For me, the takeaway is simple: B cells aren’t passive bystanders—they’re actively involved in melanoma, for better or worse. By building further on this work, we could harness their benefits while managing their suppressive roles. It could pave the way for personalised strategies leading to better outcomes.
Sam: A fine summary, Meera. And with that, it’s time to wrap up. Thank you for tuning into BJD Talks. Stay with us for more insights into the latest dermatological research. Until next time, stay curious.
